X0708 D LIVE 0001912966 REGENTIS BIOMATERIALS LTD. 60 MEDINAT HAYEHUDIM STREET HERZLIYA L3 ISRAEL 4676652 +972 (9) 960-1917 ISRAEL None None Corporation true Ehud Geller Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street Herzliya L3 ISRAEL 4676652 Executive Officer Director Ori Gon Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street60 Medinat Ha Herzliya L3 ISRAEL 4676652 Executive Officer Arie Gordashnikov Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street Herzliya L3 ISRAEL 4676652 Executive Officer Galit Reske Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street Herzliya L3 ISRAEL 4676652 Executive Officer Jeff Dykan Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street Herzliya L3 ISRAEL 4676652 Director Keith Valentine Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street Herzliya L3 ISRAEL 4676652 Director Efraim Cohen-Arazi Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street Herzliya L3 ISRAEL 4676652 Director Pini Ben-Elazar Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street Herzliya L3 ISRAEL 4676652 Director Susan Alpert Regentis Biomaterials Ltd. 60 Medinat Hayehudim Street Herzliya L3 ISRAEL 4676652 Director Biotechnology Decline to Disclose 06c false 2026-06-17 false true true true false 0 ThinkEquity LLC 000020996 None None 17 State Street 41st Floor NY NY NEW YORK 10004 AZ ARIZONA CA CALIFORNIA CT CONNECTICUT FL FLORIDA ID IDAHO IL ILLINOIS MA MASSACHUSETTS NJ NEW JERSEY NY NEW YORK WA WASHINGTON WI WISCONSIN true 6500000 6500000 0 An offering of 1,844,543 ordinary shares, 12,600 pre-funded warrants and 1,857,143 ordinary warrants, at a purchase price of $3.50 per share and ordinary warrant and $3.4999 per pre-funded warrant and ordinary warrant. false 22 455000 0 The Placement Agent also received a $180,000 accountable expense reimbursement, a non-accountable expense allowance of $65,000 and 92,857 unregistered warrants to purchase ordinary shares. 0 The Company intends to use the proceeds from the Offering to support its clinical trials and submissions to the FDA, advance its technology, support its operations and intellectual property and for working capital and general corporate purposes. false REGENTIS BIOMATERIALS LTD. /s/ Ori Gon Ori Gon Chief Financial Officer 2026-06-25